![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SNTG1 |
Gene summary for SNTG1 |
![]() |
Gene information | Species | Human | Gene symbol | SNTG1 | Gene ID | 54212 |
Gene name | syntrophin gamma 1 | |
Gene Alias | G1SYN | |
Cytomap | 8q11.21 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A024R7Y0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54212 | SNTG1 | cirrhotic2 | Human | Liver | Cirrhotic | 4.06e-02 | -7.06e-02 | 0.0201 |
54212 | SNTG1 | HCC1 | Human | Liver | HCC | 6.01e-11 | 1.11e+00 | 0.5336 |
54212 | SNTG1 | HCC2 | Human | Liver | HCC | 2.01e-05 | 2.18e-01 | 0.5341 |
54212 | SNTG1 | Pt13.a | Human | Liver | HCC | 4.06e-02 | -7.06e-02 | 0.021 |
54212 | SNTG1 | S014 | Human | Liver | HCC | 1.39e-17 | 9.44e-01 | 0.2254 |
54212 | SNTG1 | S015 | Human | Liver | HCC | 3.48e-13 | 7.53e-01 | 0.2375 |
54212 | SNTG1 | S016 | Human | Liver | HCC | 2.17e-31 | 1.23e+00 | 0.2243 |
54212 | SNTG1 | HTA12-15-2 | Human | Pancreas | PDAC | 4.47e-05 | 4.90e-01 | 0.2315 |
54212 | SNTG1 | HTA12-23-1 | Human | Pancreas | PDAC | 5.20e-08 | 8.41e-01 | 0.3405 |
54212 | SNTG1 | HTA12-25-1 | Human | Pancreas | PDAC | 3.68e-04 | 5.24e-01 | 0.313 |
54212 | SNTG1 | HTA12-26-1 | Human | Pancreas | PDAC | 2.67e-04 | 4.95e-01 | 0.3728 |
54212 | SNTG1 | HTA12-29-1 | Human | Pancreas | PDAC | 6.45e-37 | 9.89e-01 | 0.3722 |
54212 | SNTG1 | HTA12-32-1 | Human | Pancreas | PDAC | 1.11e-06 | 1.18e+00 | 0.3624 |
54212 | SNTG1 | HTA12-9-3 | Human | Pancreas | PDAC | 1.07e-02 | 5.26e-01 | 0.2045 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SNTG1 | SNV | Missense_Mutation | novel | c.1271A>T | p.Asp424Val | p.D424V | Q9NSN8 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-EI-6884-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5 | SD |
SNTG1 | insertion | Frame_Shift_Ins | novel | c.813_814insA | p.Ile274AsnfsTer18 | p.I274Nfs*18 | Q9NSN8 | protein_coding | TCGA-AA-3837-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
SNTG1 | SNV | Missense_Mutation | novel | c.955C>A | p.Leu319Met | p.L319M | Q9NSN8 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SNTG1 | SNV | Missense_Mutation | novel | c.1321G>T | p.Gly441Cys | p.G441C | Q9NSN8 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNTG1 | SNV | Missense_Mutation | novel | c.1397A>T | p.Glu466Val | p.E466V | Q9NSN8 | protein_coding | deleterious(0.03) | probably_damaging(0.966) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SNTG1 | SNV | Missense_Mutation | c.680G>A | p.Arg227Gln | p.R227Q | Q9NSN8 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SNTG1 | SNV | Missense_Mutation | novel | c.310N>A | p.Ala104Thr | p.A104T | Q9NSN8 | protein_coding | tolerated(0.09) | possibly_damaging(0.459) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
SNTG1 | SNV | Missense_Mutation | c.613G>A | p.Asp205Asn | p.D205N | Q9NSN8 | protein_coding | deleterious(0.05) | probably_damaging(0.972) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNTG1 | SNV | Missense_Mutation | c.33N>T | p.Lys11Asn | p.K11N | Q9NSN8 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SNTG1 | SNV | Missense_Mutation | c.641N>T | p.Ser214Leu | p.S214L | Q9NSN8 | protein_coding | deleterious(0) | benign(0.026) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |